OncoMatch/Clinical Trials/NCT05990192
SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
Is NCT05990192 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Niraparib oral capsule for ovarian cancer recurrent.
Treatment: Niraparib oral capsule — SOPRANO is a multi-centre, randomised phase II trial which aims to assess the impact of Stereotactic radiotherapy (SBRT) and continuing treatment with a PARP inhibitor (PARPi) for patients with oligometastatic or oligoprogressive ovarian, fallopian tube and primary peritoneal carcinoma. SOPRANO will also establish the feasibility and acceptability of delivering SBRT in this setting.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: PARP inhibitor — last systemic therapy
Radiological disease progression whilst on, or following, any prior PARP inhibitor therapy. The PARP inhibitor is required to have been the patient's last systemic therapy.
Cannot have received: investigational medicinal product
Treatment with any other investigational medicinal product (IMP) within the 4 weeks prior to trial entry.
Cannot have received: radiotherapy
Exception: prior radiotherapy near the oligometastatic / oligoprogressive lesion precluding ablative SBRT
Prior radiotherapy near the oligometastatic / oligoprogressive lesion precluding ablative SBRT.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05990192 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational medicinal product, radiotherapy disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages